OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 27, 2022.
"This risk-to-benefit profile has a different connotation for patients because, although a therapy may improve certain aspects of their disease, it may also have a substantial impact on their quality of life.”
Investigators believe that “screening for comorbidities of COPD and diabetes mellitus with end-organ damage as part of the routine in treating RA-ILD population" may be beneficial.
"Cardiovascular manifestations in rheumatoid arthritis can be complex, raising concerns for adequate patient management and provider-dependent roles.”
Rheumatology Network interviewed Paul M Peloso, MD, MSc, Chief Medical Officer at Acelyrin, to discuss recent phase 2 data examining the safety and efficacy of izokibep in the treatment of psoriatic arthritis.
Although pulmonary complications in pediatric patients may cause functional impairment and increase mortality, studies detecting lung involvement in children with treatment-naïve, newly diagnosed patients with rheumatic disease are scarce.